Citadel Advisors’s MEDIROM Healthcare Technologies MRM Stock Holding History

Citadel Advisors’s Portfolio MRM Stock Details MRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,217	Closed	-$26.9K	–	13619
2025 Q2	$26.9K	Sell	19,217 -48,211	-71%	-$53.3K	﹤0.01%	12029
2025 Q1	$24.7K	Buy	+67,428	New	+$53.2K	﹤0.01%	12987
2021 Q2	–	Sell	-19,626	Closed	-$218K	–	14118
2021 Q1	$218K	Buy	+19,626	New	+$248K	﹤0.01%	11530

Other funds holding MRM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citadel Advisors's MRM Position: Q3 2025 in Review

Citadel Advisors sold out of MEDIROM Healthcare Technologies (MRM) in Q3 2025, closing a stake of 19,217 shares — an estimated $26.9K sold.

Citadel Advisors first reported a position in MRM in Q1 2021 and held it in 3 quarters. The position peaked at $218K in Q1 2021. 4 funds tracked by Wall St. Rank hold MRM as of Q3 2025.

Citadel Advisors reported no remaining MEDIROM Healthcare Technologies position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 19,217 MEDIROM Healthcare Technologies shares in Q3 2025, an estimated $26.9K.
Citadel Advisors first reported a position in MEDIROM Healthcare Technologies in Q1 2021 and held it in 3 quarters.
Citadel Advisors's MEDIROM Healthcare Technologies position peaked at $218K in Q1 2021.
4 funds tracked by Wall St. Rank held MEDIROM Healthcare Technologies as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.